Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Net Margin: 2020-2025

Historic Net Margin for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -6.54%.

  • GeneDx Holdings' Net Margin rose 427.00% to -6.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year increase of 3175.00%. This contributed to the annual value of -17.12% for FY2024, which is 6965.00% up from last year.
  • As of Q3 2025, GeneDx Holdings' Net Margin stood at -6.54%, which was down 162.13% from 10.53% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Net Margin registered a high of 75.80% during Q3 2021, and its lowest value of -503.20% during Q4 2022.
  • Moreover, its 3-year median value for Net Margin was -32.39% (2024), whereas its average is -40.35%.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by 43,368bps in 2022, then surged by 45,831bps in 2023.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Net Margin stood at -69.52% in 2021, then tumbled by 43,368bps to -503.20% in 2022, then surged by 45,831bps to -44.89% in 2023, then spiked by 5,057bps to 5.69% in 2024, then skyrocketed by 427bps to -6.54% in 2025.
  • Its Net Margin stands at -6.54% for Q3 2025, versus 10.53% for Q2 2025 and -7.49% for Q1 2025.